Literature DB >> 9890995

Definition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD22.

J Blasioli1, S Paust, M L Thomas.   

Abstract

CD22 phosphorylation is an early event of B cell antigen receptor engagement and results in the recruitment of the negative regulatory tyrosine phosphatase, SHP-1. Peptides representing the potential phosphorylation sites within the cytoplasmic domain of CD22 have been used to stimulate SHP-1 catalytic activity and to inhibit the binding of SHP-1 to CD22 (Doody, G., Justement, L., Delibrias, C., Matthews, R., Lin, J., Thomas, M., and Fearon, D. (1995) Science 269, 242-244). However, the sites of phosphorylation within the cytoplasmic domain of CD22 and the importance of each for the recruitment and activation of SHP-1 remain unknown. Here we demonstrate that there are multiple sites within the cytoplasmic domain of CD22 that interact with the Src homology 2 domains of SHP-1. Nevertheless, a minimum of two tyrosines in CD22 is required for the association with SHP-1. Furthermore, both Src homology 2 domains of SHP-1 are necessary for efficient binding to CD22.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9890995     DOI: 10.1074/jbc.274.4.2303

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2.

Authors:  Z Yu; M Maoui; L Wu; D Banville; S Shen
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

Review 2.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

Review 3.  The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease.

Authors:  Jennifer Müller; Lars Nitschke
Journal:  Nat Rev Rheumatol       Date:  2014-04-29       Impact factor: 20.543

4.  Visualization of negative signaling in B cells by quantitative confocal microscopy.

Authors:  H Phee; W Rodgers; K M Coggeshall
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

5.  CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling.

Authors:  Jennifer Müller; Ingrid Obermeier; Miriam Wöhner; Carolin Brandl; Sarah Mrotzek; Sieglinde Angermüller; Palash C Maity; Michael Reth; Lars Nitschke
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-08       Impact factor: 11.205

6.  CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.

Authors:  Fatih M Uckun; Patricia Goodman; Hong Ma; Ilker Dibirdik; Sanjive Qazi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-14       Impact factor: 11.205

7.  Identification of natural killer cell receptor genes in the genome of the marsupial Tasmanian devil (Sarcophilus harrisii).

Authors:  Lauren E van der Kraan; Emily S W Wong; Nathan Lo; Beata Ujvari; Katherine Belov
Journal:  Immunogenetics       Date:  2012-09-25       Impact factor: 2.846

Review 8.  Signaling defects in anti-tumor T cells.

Authors:  Alan B Frey; Ngozi Monu
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

9.  src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation.

Authors:  Tohru Kamata; Masakatsu Yamashita; Motoko Kimura; Kaoru Murata; Masamichi Inami; Chiori Shimizu; Kaoru Sugaya; Chrong-Reen Wang; Masaru Taniguchi; Toshinori Nakayama
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

10.  Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model.

Authors:  Kyle J Bednar; Elena Shanina; Romain Ballet; Edward P Connors; Shiteng Duan; Joana Juan; Britni M Arlian; Michael D Kulis; Eugene C Butcher; Wai-Ping Fung-Leung; Tadimeti S Rao; James C Paulson; Matthew S Macauley
Journal:  J Immunol       Date:  2017-09-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.